Non Small Cell Lung Cancer Clinical Trials in Lake Success, New York

9 studies are recruiting for non small cell lung cancer in Lake Success, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwell Health - Monter Cancer Center /ID# 247081, Lake Success, New York

   Locations

   317 in total

   Run by

   AbbVie

   See if you can join NCT04928846 on ClinicalTrials.gov

2. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

   A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 107 - START New York - Long Island, Lake Success, New York

   Locations

   6 in total

   Run by

   EpiBiologics

   See if you can join NCT07462377 on ClinicalTrials.gov

3. A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

   This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START NY Long Island, Lake Success, New York

   Locations

   15 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT07361562 on ClinicalTrials.gov

4. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

   Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwell Health/R.J. Zuckerberg Cancer Center, Lake Success, New York

   Locations

   118 in total

   Run by

   ArriVent BioPharma, Inc.

   See if you can join NCT07185997 on ClinicalTrials.gov

5. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START-New York Long Island, Lake Success, New York

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

6. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwell Health, Lake Success, New York

   Locations

   47 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

7. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

   This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwell Health/Center for Advanced Medicine, Lake Success, New York

   Locations

   75 in total

   Run by

   Canadian Cancer Trials Group

   See if you can join NCT06686771 on ClinicalTrials.gov

8. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

   This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START New York Long Island, LLC, Lake Success, New York

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07503808 on ClinicalTrials.gov

9. IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

   In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung c…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics, Lake Success, New York

   Locations

   30 in total

   Run by

   Innate Pharma

   See if you can join NCT05742607 on ClinicalTrials.gov